What is the official ID of this bill?
The official print number for this legislation is HR 2666.
New Medicaid Drug Purchasing Rules: Patient Benefits
The MVP Act introduces changes to how drugs are purchased under the Medicaid program, allowing flexible, outcome-based pricing agreements. This aims to improve access to innovative therapies, reduce costs for patients and the healthcare system, and increase the efficiency of public drug spending.
Key points
Improved access to innovative drugs: Manufacturers can offer varying prices based on treatment outcomes, potentially facilitating access to expensive but effective therapies, such as gene therapies.
Potential savings for patients and the state: If a drug does not achieve expected results, the manufacturer may refund part of the cost, reducing financial risk for patients and public programs.
Greater transparency in drug pricing: New rules aim for better price reporting, which could lead to fairer and more efficient price negotiations.
Protection against abuse: The act introduces exceptions to anti-kickback statutes for these arrangements, encouraging their use while ensuring oversight.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.